Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum
- 30 April 1994
- journal article
- research article
- Published by Elsevier BV in Immunopharmacology
- Vol. 27 (2), 145-153
- https://doi.org/10.1016/0162-3109(94)90049-3
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activitiesBiochemistry, 1988
- Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3bMolecular Immunology, 1983
- Potentiation of factor H by heparin: A rate-limiting mechanism for inhibition of the alternative complement pathwayMolecular Immunology, 1983
- Polyions regulate the alternative amplification pathway of complementImmunopharmacology, 1983
- A postulated mechanism for heparin's potentiation of C1 inhibitor functionMolecular Immunology, 1982
- Structural Determinants of the Capacity of Heparin to Inhibit the Formation of the Human Amplification C3 ConvertaseJCI Insight, 1981
- Human C4-binding protein. I. Isolation and characterizationThe Journal of Experimental Medicine, 1978
- Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin.The Journal of Experimental Medicine, 1978
- Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serumImmunochemistry, 1966
- Anticomplementary Power of HeparinThe Journal of Infectious Diseases, 1929